
Myomo (MYO) Stock Forecast & Price Target
Myomo (MYO) Analyst Ratings
Bulls say
Myomo Inc. has demonstrated a robust growth trajectory in its reimbursement pipeline, which increased to 1,669 units, reflecting a positive trend from 1,389 units in the previous quarter. Additionally, with approximately 22% of projected revenue in 2024 coming from orthotics and prosthetics providers, the company is strategically redirecting its growth towards this burgeoning Medicare market. Furthermore, the recent positive ruling from the Centers for Medicare & Medicaid Services significantly expands the potential market for the MyoPro, positioning Myomo for enhanced financial performance and growth opportunities.
Bears say
Myomo Inc has significantly lowered its 2025 revenue guidance from $50 – 53 million to $40 – 42 million, indicating a notable decline in expected financial performance. Additionally, the company has reported a decrease in its insurance authorized backlog, which fell from 272 in Q4 to 208, suggesting a reduction in future sales potential. Despite potential growth opportunities, recent weaknesses in marketing effectiveness and lead quality have adversely impacted pipeline conversions, raising concerns about the company’s ability to meet its revised targets.
This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.
Myomo (MYO) Analyst Forecast & Price Prediction
Start investing in Myomo (MYO)
Order type
Buy in
Order amount
Est. shares
0 shares